Board of Directors

Barr Dolan

Mr. Dolan has been investing in life sciences companies for the last twenty years as a founding partner in Charter Venture Capital. He has been an active founder of multiple life sciences companies, including the women's health company Adeza Biomedical, cardiac catheter company EP Technologies (IPO, then acquired by Boston Scientific), biotech company Heska Corporation (HSKA), biotech company Univax Biologics (IPO, then acquired by NABI), women's health drug delivery company UMD and women's health medical device company Vesta (acquired by Pfizer). Among his many roles with these companies, Mr. Dolan has also served as interim chief executive officer of Adeza and EP Technologies and chairman of several others.

Back to Top

Timothy Petersen

In 2002, Mr. Peterson joined partner Jan Garfinkle in launching Arboretum Ventures and serves on Board of Directors of Advanced ICU Care, HealthMedia, KFx Medical, and Thermocure, four of Arboretum's portfolio investments, and previously sat on the Board of Asterand (LSE: ATD). Immediately prior to Arboretum, Mr. Peterson was the Managing Director of the Zell Lurie Institute for Entrepreneurial Studies at the University of Michigan. He also directed the activities of the Wolverine Venture Fund, an evergreen fund that includes the active participation of Michigan's MBA students. Previously, Mr. Peterson spent nine years at Industrial Economics, Inc., becoming a member of the firm's senior management team in 1991. Industrial Economics, founded in the early 1980's in Cambridge, MA, is a leader in the fields of natural resource economics and environmental science.

Back to Top

John Savarese, M.D.

Dr. Savarese is a Managing Director at Montreux Equity Partners. Prior to joining Montreux, Dr. Savarese served as Director of Business Development and Marketing with the entrepreneurial team at NeurogesX (NASDAQ: NGSX), a Montreux portfolio company focused on the treatment of pain. Dr. Savarese worked in the Life Sciences Investment Banking division at Credit Suisse First Boston and started his career in the venture industry as a consultant to private equity firms and early stage companies.

Dr. Savarese's clinical experience in General and Orthopedic Surgery was gained at the Cornell University Medical College/Hospital for Special Surgery. Dr. Savarese is a board director or observer for Montreux portfolio companies, KFx, Verus, Avantis Medical, Bayhill and Novalar. In addition, he was actively involved in Montreux's investment decisions in Somaxon (NASDAQ: SOMX), Aryx (NASDAQ: ARYX), Orexigen (NASDAQ: OREX), Cerexa (Forest Labs), Renal CarePartners, NovoStent and Asthmatx.

Back to Top

W. Tate Scott

Mr. Scott is experienced in drugs, devices, and combination products at majors American Hospital Supply and Johnson & Johnson as well as President/CEO of both public and start-ups companies. He served as Chairman of Orquest, Inc. (Orthobiologics) through its sale in 2003 to Depuy, a Johnson and Johnson Company, and is currently on the boards of Scott Laboratories (Grace Clinic http://www.graceclinicus.com/) and Benvenue Medical (http://www.benvenuemedical.com/) . In addition to his experience in orthopaedics, Mr. Scott has brought products to Urology, Nursing Products, and General Surgery Markets and is the holder of 5 patents. While at Ethicon Endo Surgery, Mr. Scott led the business development and M&A activities for the general surgery franchise. His AB and MBA were earned at Duke University.

Back to Top

Stephen Snowdy, Ph.D (Board Observer)

Dr. Stephen Snowdy joined MB Ventures in early 2003, having been the first person to earn simultaneous PhD and MBA degrees at the University of North Carolina, Chapel Hill. Stephen serves on the Board of Directors of Protein Discovery, Inc., Alveolus, Inc., and is an observer on the boards of Kereos, Inc. and KFx, Inc. He also is a board member of Southeast BIO, a regional non-profit organization that fosters life sciences entrepreneurship in the Southeast.

Back to Top

Craig Taylor

Craig C. Taylor has been an active venture capitalist since 1977. He earned a BS (1972) and an MS (1974) in physics from Brown University, and an MBA from Stanford in 1977. He worked in the Office of Technology Licensing at Stanford from 1975 to 1977. He is a director of Adeza Biomedical (NASDAQ:ADZA) and serves on the board of directors of several private companies, including ForteBio, Labcyte, Optimedica, and Zyomyx. Mr. Taylor is a past member of the Board of Directors of the National Venture Capital Association, and serves on the Board of Advisors of the MIT/Stanford Venture Laboratory.

Back to Top

Rod Young

Mr. Young joined Three Arch Partners as a Venture Partner in May 2006. Prior to Three Arch Partners, Rod was President and CEO of Vivant Medical, a Three Arch Partners medical device company that was acquired by Tyco; President & CEO of Targesome; Chairman & CEO of General Surgical Innovations, also a Three Arch Partners medical device company that was acquired by Tyco; President & CEO of Focus Surgery; President of Toshiba America MRI; and President & COO of Diasonics.

Rod holds a BS degree in Industrial Engineering from Stanford University and an MBA from The Harvard Business School.

Back to Top